StoxSyngene International vs Cohance Lifesciences: share price & financials comparison
NSE: SYNGENE vs COHANCE · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Syngene International vs Cohance Lifesciences at a glance
Syngene International (SYNGENE) has a market capitalisation of ₹16,846 Cr, against ₹16,588 Cr for Cohance Lifesciences (COHANCE). Over the past year Syngene International has returned -36.7%, compared with -44.9% for Cohance Lifesciences. On valuation, Cohance Lifesciences trades at a lower P/E of 156.1 versus 441.0. Cohance Lifesciences earns a higher return on equity (2.7% vs 0.8%). Syngene International comes out ahead on financial health and momentum. Cohance Lifesciences comes out ahead on size, profitability and technicals. Across the scored metrics below, Syngene International leads on 7 and Cohance Lifesciences on 8. On StoxGud's 10-point checklist, Syngene International scores 3/10 and Cohance Lifesciences scores 3/10.
| Metric | Syngene International | Cohance Lifesciences |
|---|---|---|
| Size | ||
| Market cap | ₹16,846 Cr | ₹16,588 Cr |
| Revenue (latest FY) | ₹3,739 Cr | ₹2,269 Cr |
| Net profit (latest FY) | ₹0 Cr | ₹179 Cr |
| Valuation | ||
| P/E | 441.0 | 156.1 |
| P/B | 3.47 | 4.24 |
| Dividend yield | 0.30% | — |
| Profitability | ||
| Return on equity | 0.8% | 2.7% |
| Net profit margin | 1.1% | 5.0% |
| Operating margin | 21.3% | 14.8% |
| Growth | ||
| Revenue growth (YoY) | -8.6% | -23.1% |
| Net profit growth (YoY) | — | -149.3% |
| Revenue CAGR (multi-year) | +11.3% | +18.2% |
| Financial health | ||
| Debt to equity | 0.01 | 0.04 |
| Momentum | ||
| 1-month return | +15.8% | -4.8% |
| 1-year return | -36.7% | -44.9% |
| 3-year CAGR | -16.4% | -8.8% |
| 5-year CAGR | -5.3% | -2.9% |
| 10-year CAGR | +4.3% | — |
| Distance from 52W high | -37.1% | -44.3% |
| Technicals | ||
| RSI (14) | 60 | 39 |
| Price vs 200-day avg | -1.8% | +5.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Syngene International | Cohance Lifesciences |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✗ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 3/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Syngene International or Cohance Lifesciences?
Syngene International has a market cap of ₹16,846 Cr and Cohance Lifesciences has a market cap of ₹16,588 Cr as of 06 Nov 2026.
Which has a lower P/E, Syngene International or Cohance Lifesciences?
Cohance Lifesciences has the lower P/E: Syngene International trades at 441.0 and Cohance Lifesciences at 156.1.
Which gave better returns in the last year, Syngene International or Cohance Lifesciences?
Syngene International did better: Syngene International returned -36.7% and Cohance Lifesciences returned -44.9% over one year.
Is Syngene International or Cohance Lifesciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Syngene International scores 3/10 and Cohance Lifesciences scores 3/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.